Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.53 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetraxetan SCHEMBL3364489 | 1.00 | HSD17B10 (0.54) | HSD17B10SLC6A9GLRA1OR51E2KDM4E | |
| Tetraxetan SCHEMBL1496261 | 0.90 | HSD17B10 (0.50) | HSD17B10SLC6A9GLRA1OR51E2KDM4E | |
| SCHEMBL321989 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 | |
| Tetraxetan SCHEMBL2635294 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 | |
| SCHEMBL3660521 | 0.89 | — | — | |
| SCHEMBL173508 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 | |
| Tetraxetan SCHEMBL18018 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 | |
| Tetraxetan SCHEMBL2017956 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 | |
| SCHEMBL6848102 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 | |
| SCHEMBL6744121 | 0.89 | HSD17B10 (0.64) | HSD17B10SLC6A9KDM4ES1PR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240178458-A1 | ORGANIC-INORGANIC COMPOSITE FILM AND LITHIUM BATTERY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2024-05-30 | — | — | US | claimed |
| US-4252655-A | ADDING ORGANIC ZINC CHELATE | HALLIBURTON COMPANY (US) | 1981-02-24 | — | — | US | claimed |
| US-20240178458-A1 | ORGANIC-INORGANIC COMPOSITE FILM AND LITHIUM BATTERY | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2024-05-30 | — | — | US | disclosed |
| US-10974059-B2 | Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field | NANOBACTERIE (FR) | 2021-04-13 | — | — | US | disclosed |
| US-20190201704-A1 | TREATMENT OF CANCER OR TUMORS INDUCED BY THE RELEASE OF HEAT GENERATED BY VARIOUS CHAINS OF MAGNETOSOMES EXTRACTED FROM MAGNETOTACTIC BACTERIA AND SUBMITTED TO AN ALTERNATING MAGNETIC FIELD | NANOBACTERIE (FR) | 2019-07-04 | — | — | US | disclosed |
| US-10252073-B2 | Treatment of cancer or tumor induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field | NANOBACTERIE (FR) | 2019-04-09 | — | — | US | disclosed |
| US-10238886-B2 | Treatment of cancer or tumors induced by the release of heat generated by various chains of magnetosomes extracted from magnetotactic bacteria and submitted to an alternating magnetic field | NANOBACTERIE (FR) | 2019-03-26 | — | — | US | disclosed |
| US-20170157253-A1 | TREATMENT OF CANCER OR TUMOR INDUCED BY THE RELEASE OF HEAT GENERATED BY VARIOUS CHAINS OF MAGNETOSOMES EXTRACTED FROM MAGNETOTACTIC BACTERIA AND SUBMITTED TO AN ALTERNATING MAGNETIC FIELD | ALPHAONCO (FR) | 2017-06-08 | — | — | US | disclosed |
| EP-2370085-B1 | TREATMENT OF CANCER OR TUMOR INDUCED BY THE RELEASE OF HEAT GENERATED BY VARIOUS CHAINS OF MAGNETOSOMES EXTRACTED FROM MAGNETOTACTIC BACTERIA AND SUBMITTED TO AN ALTERNATIVE MAGNETIC FIELD | NANOBACTERIE (FR) | 2015-04-15 | — | — | EP | disclosed |
| US-20120302819-A1 | TREATMENT OF CANCER OR TUMORS INDUCED BY THE RELEASE OF HEAT GENERATED BY VARIOUS CHAINS OF MAGNETOSOMES EXTRACTED FROM MAGNETOTACTIC BACTERIA AND SUBMITTED TO AN ALTERNATIVE MAGNETIC FIELD | NANOBACTERIE | 2012-11-29 | — | — | US | disclosed |
| US-8092705-B2 | Simple method for introducing magnetic particles into a polymer | BEIJING DINGGUOCHANGSHENG BIOTECH, CO. LTD. (CN) | 2012-01-10 | — | — | US | disclosed |
| US-20080090091-A1 | Polyimide Based Compositions Comprising Doped Polyaniline and Methods and Compositions Relating Thereto | DUPONT ELECTRONICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7316791-B2 | Polyimide based substrate comprising doped polyaniline | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060199115-A1 | Photothermographic material and image forming method | FUJIFILM CORPORATION (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1244612-B1 | PROCESS FOR PREPARING ALKYLENE DIAMINE TRIACETIC ACID | AKZO NOBEL NV (NL) | 2005-08-31 | — | — | EP | disclosed |
| EP-1553142-A2 | Polyimide based compositions comprising doped polyaniline and methods relating thereto | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20050145832-A1 | POLYIMIDE BASED COMPOSITIONS COMPRISING DOPED POLYANILINE AND METHODS AND COMPOSITIONS RELATING THERETO | DUPONT ELECTRONICS, INC. | 2005-07-07 | — | — | US | disclosed |
| US-20040142287-A1 | Photothermographic material and image forming method | FUJI PHOTO FILM CO., LTD. (JP) | 2004-07-22 | — | — | US | disclosed |
| US-6492549-B2 | HYDROLYZING ALKYLENE DIAMINE (DERIVATIVE) TO A SALT OF AN ALKYLENE DIAMINE TRIACETIC ACID (DERIVATIVE) IN PRESENCE OF POLYVALENT METAL ION (CALCIUM); HIGH PURITY; CHELATION, METAL CLEANING | AKZO NOVEL NV (NL) | 2002-12-10 | — | — | US | disclosed |
| US-20010007042-A1 | Process for preparing alkylene diamine triacetic acid | NOURYON CHEMICALS INTERNATIONAL B.V. (NL) | 2001-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007042-A1 | Process for preparing alkylene diamine triacetic acid | NAAA, PTMA, AADAT | HSD17B10 3630/4885SLC6A9 190/4885GLRA1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.